{"id":"W2593423583","doi":"10.1016/s2352-3018(17)30031-0","title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study","year":2017,"lang":"en","type":"article","venue":"The Lancet HIV","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":false,"ca_institutions":"Providence Health Care","funders":"Gilead Sciences","keywords":"Rilpivirine; Emtricitabine; Tenofovir alafenamide; Medicine; Regimen; Placebo; Cobicistat; Internal medicine; Tolerability; Clinical endpoint; Pharmacology; Randomized controlled trial; Human immunodeficiency virus (HIV); Virology; Adverse effect; Viral load; Antiretroviral therapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005291071,0.0005488744,0.001201374,0.0002016517,0.0005694526,0.0002361004,0.00030745,0.00008946337,0.00004101994],"category_scores_gemma":[0.00007793545,0.0003015608,0.00006078508,0.0003072621,0.0001053664,0.0004143657,0.0002112453,0.000466048,0.00007186406],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001641337,"about_ca_system_score_gemma":0.0001942431,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001872045,"about_ca_topic_score_gemma":0.006746732,"domain_scores_codex":[0.9975188,0.00009994963,0.0005344872,0.000707769,0.0004806669,0.0006582642],"domain_scores_gemma":[0.9979421,0.0001590506,0.0003297538,0.001136594,0.0001514038,0.0002810908],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.2469337,0.001924612,0.739083,0.00007549929,0.0006340816,0.000544236,0.008153846,0.0000921846,0.0007086361,0.000004677805,0.0001487477,0.001696744],"study_design_scores_gemma":[0.4623238,0.0009382775,0.5317536,0.0005389266,0.0005106399,0.00002950495,0.0004581249,0.002084271,0.0007210553,0.00001495322,0.0002316328,0.0003952155],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.988066,0.00005667927,0.0003076897,0.004248276,0.00006866809,0.005994461,0.00005402908,0.0001245569,0.001079683],"genre_scores_gemma":[0.9962814,0.00007411539,0.0009264661,0.0001668577,0.0002550689,0.0004879895,0.0001694057,0.00006130722,0.001577327],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2153901,"threshold_uncertainty_score":0.9999437,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02301780583860628,"score_gpt":0.3063705951627395,"score_spread":0.2833527893241332,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}